全文获取类型
收费全文 | 16567篇 |
免费 | 1374篇 |
国内免费 | 33篇 |
专业分类
耳鼻咽喉 | 158篇 |
儿科学 | 524篇 |
妇产科学 | 561篇 |
基础医学 | 2154篇 |
口腔科学 | 291篇 |
临床医学 | 2137篇 |
内科学 | 2986篇 |
皮肤病学 | 216篇 |
神经病学 | 1687篇 |
特种医学 | 438篇 |
外科学 | 1932篇 |
综合类 | 258篇 |
一般理论 | 21篇 |
预防医学 | 1597篇 |
眼科学 | 412篇 |
药学 | 1085篇 |
中国医学 | 38篇 |
肿瘤学 | 1479篇 |
出版年
2023年 | 105篇 |
2022年 | 96篇 |
2021年 | 258篇 |
2020年 | 226篇 |
2019年 | 300篇 |
2018年 | 279篇 |
2017年 | 235篇 |
2016年 | 296篇 |
2015年 | 312篇 |
2014年 | 440篇 |
2013年 | 634篇 |
2012年 | 1008篇 |
2011年 | 1011篇 |
2010年 | 543篇 |
2009年 | 526篇 |
2008年 | 1010篇 |
2007年 | 905篇 |
2006年 | 924篇 |
2005年 | 863篇 |
2004年 | 890篇 |
2003年 | 923篇 |
2002年 | 828篇 |
2001年 | 497篇 |
2000年 | 450篇 |
1999年 | 404篇 |
1998年 | 185篇 |
1997年 | 171篇 |
1996年 | 141篇 |
1995年 | 148篇 |
1994年 | 126篇 |
1993年 | 116篇 |
1992年 | 249篇 |
1991年 | 254篇 |
1990年 | 222篇 |
1989年 | 204篇 |
1988年 | 193篇 |
1987年 | 194篇 |
1986年 | 156篇 |
1985年 | 169篇 |
1984年 | 107篇 |
1983年 | 92篇 |
1982年 | 79篇 |
1981年 | 69篇 |
1979年 | 116篇 |
1978年 | 90篇 |
1977年 | 74篇 |
1975年 | 66篇 |
1974年 | 79篇 |
1972年 | 82篇 |
1970年 | 79篇 |
排序方式: 共有10000条查询结果,搜索用时 312 毫秒
1.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献2.
Well‐being,health and fitness of children who use wheelchairs: Feasibility study protocol to develop child‐centred ‘keep‐fit’ exercise interventions 下载免费PDF全文
3.
4.
5.
Valerie Iles 《Health care analysis》2016,24(2):105-118
This paper takes a somewhat slant perspective on flourishing and care in the context of suffering, death and dying, arguing that care in this context consists principally of ‘acts of work and courage that enable flourishing’. Starting with the perception that individuals, society and health care professionals have become dulled to death and the process of dying in Western advanced health systems, it suggests that for flourishing to occur, both of these aspects of life need to be faced more directly. The last days of life need to be ‘undulled’. Reflections upon the experiences of the author as carer and daughter in the face of her mother’s experience of death are used as basis for making suggestions about how care systems and professionals might better assist people in dealing with ‘the most grown up thing’ humans ever do, which is to die. 相似文献
6.
The serrated pathway (SP) can be viewed as two parallel, but partially overlapping, arrays of colorectal precursor lesions, and their respective endpoint carcinomas, that are distinct from those of the conventional adenoma–carcinoma sequence (APC‐pathway). In this review we focus at the outset on the clinical impact, pathological features, molecular genetics and biological behaviours of the various SP cancers. Then we summarize the clinicopathological features, classification and molecular profiles of the two main precursor lesions that anchor the respective pathways: (i) sessile serrated adenoma/polyp (SSA/P), also called sessile serrated lesion (SSL), and (ii) traditional serrated adenoma (TSA). Activating mutations of the RAS–RAF–MAPK pathway initiate and sustain the lesions of the SP, and CpG island methylation of the promoter regions of tumour suppressor and DNA repair genes play the major role in their neoplastic progression. The SP includes microsatellite stable (MSS) carcinomas that are among the most biologically aggressive colorectal carcinomas (CRC), and also accounts for the great preponderance of sporadic hypermutated, mismatch repair (MMR)‐deficient or microsatellite instable (MSI) CRC. The identification, removal and appropriate classification of at‐risk SP precursors and surveillance of individuals who harbour these lesions present a challenge and opportunity for CRC prevention and mortality reduction. 相似文献
7.
8.
9.
10.